Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study - Summary - MDSpire
Advertisement
Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study
To evaluate the efficacy and safety of immunotherapy with or without low-intensity chemotherapy compared to standard chemotherapy in fit patients newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL).
Key Findings:
The IG achieved a higher MRD negativity rate (88% vs. 48%, p = 0.002), indicating superior treatment efficacy.
The IG had a higher median minimum neutrophil count (p < 0.001) and platelet count (p = 0.001), suggesting better hematologic recovery.
The duration of neutrophil count < 0.5 × 10^9/L was shorter in the IG (p = 0.033), reflecting reduced hematologic toxicity.
Fewer pulmonary infections were reported in the IG (44% vs. 84%, p = 0.003), highlighting improved safety.
The IG required fewer red blood cell transfusions (4 vs. 8 u, p = 0.012) and platelet transfusions (0 vs. 48 u, p < 0.001), indicating lower treatment burden.
Interpretation:
An immunotherapy-based first-line treatment strategy showed promising early treatment responses and tolerability to hematologic toxicity in fit patients newly diagnosed with B-ALL, suggesting a potential shift in treatment paradigms.
Limitations:
The study is retrospective and limited to a single center, which may introduce selection bias.
The sample size is relatively small, which may affect the generalizability of the findings.
Conclusion:
These exploratory findings provide additional real-world evidence for the use of immunotherapy in first-line treatment of B-ALL.
